SEC Form 4 · accession 0001445064-15-000079
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Don M Bailey
Director
Period of report
Apr 13, 2015
Accepted (ET)
Apr 14, 2015 · 5:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Apr 13, 2015 | M | 40,000 | $26.95 | A | 179,607 | D | |
| Ordinary SharesF2 | Apr 13, 2015 | S | 27,540 | $127.31 | D | 152,067 | D | |
| Ordinary SharesF3 | Apr 13, 2015 | S | 11,560 | $128.19 | D | 140,507 | D | |
| Ordinary SharesF4 | Apr 13, 2015 | S | 900 | $129.21 | D | 139,607 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F5 | $26.95 | Apr 13, 2015 | M | 40,000 | D | — | Feb 15, 2022 | Ordinary Shares | 40,000 | 51,417 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on November 26, 2014.
- F2This represents the weighted average price paid for the shares. The shares were sold at prices ranging from $126.87 to $127.85, inclusive. Mr. Bailey will provide, upon request of the SEC staff, Mallinckrodt plc, or a shareholder of Mallinckrodt plc complete information regarding the number of shares sold at each price within the ranges set forth in footnotes (2) - (4) to this Form 4.
- F3This represents the weighted average price paid for the shares. The shares were sold at prices ranging from $127.89 to $128.89, inclusive.
- F4This represents the weighted average price paid for the shares. The shares were sold at prices ranging from $128.93 to $129.54, inclusive.
- F5Represents options to purchase shares of Questcor Pharmaceuticals, Inc. that were converted into options to purchase ordinary shares of Mallinckrodt plc pursuant to the Agreement and Plan of Merger, dated as of April 5, 2014, by and among Mallinckrodt plc ("Mallinckrodt"), Questcor Pharmaceuticals, Inc. ("Questcor") and Quincy Merger Sub, Inc. All unvested options were accelerated on August 14, 2014 in connection with the acquisition of Questcor by Mallinckrodt.